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Background: Antimicrobial resistance is a major challenge in treating infectious
diseases. Therapeutic drug monitoring (TDM) can optimize and personalize antibiotic
treatment. Previously, antibiotic concentrations in tissues were extrapolated from skin
blister studies, but sweat analyses for TDM have not been conducted.
Objective: To investigate the potential of sweat analysis as a non-invasive, rapid, and
potential bedside TDM method.
Methods: We analyzed sweat and blood samples from 13 in-house patients treated
with intravenous cefepime, imipenem, or flucloxacillin. For cefepime treatment, full
pharmacokinetic sampling was performed (five subsequent sweat samples every 2 h)
using ultra-high-performance liquid chromatography coupled with triple quadrupole
mass spectrometry. The ClinicalTrials.gov registration number is NCT03678142.
Results: In this study, we demonstrated for the first time that flucloxacillin, imipenem,
and cefepime are detectable in sweat. Antibiotic concentration changes over time
demonstrated comparable (age-adjusted) dynamics in the blood and sweat of patients
treated with cefepime. Patients treated with standard flucloxacillin dosage showed the
highest mean antibiotic concentration in sweat.
Conclusions: Our results provide a proof-of-concept that sweat analysis could
potentially serve as a non-invasive, rapid, and reliable method to measure antibiotic
concentration and as a surrogate marker for tissue penetration. If combined with
smart biosensors, sweat analysis may potentially serve as the first lab-independent,
non-invasive antibiotic TDM method.
Keywords: sweat, therapeutic drug monitoring, antimicrobial resistance, antibiotics, cefepime, imipenem,
flucloxacillin
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INTRODUCTION
Antimicrobial resistance (AMR) is significantly impacting the
prevention and treatment of infectious diseases on a global
scale (1). The misuse and overuse of antibiotics (ABs)
accelerate the development of AMR (2). Multidrug-resistant
organisms (MDROs) threaten global health, food security,
and development (2). Data from the European Antimicrobial
Resistance Surveillance Network (EARS-Net) suggests that
MDROs were responsible for approximately>670,000 infections
and >30,000 deaths in the European Union in 2015 (3).
Infections caused by AB-resistant bacteria are associated with
a higher rate of complications and require significantly more
resources than those from non-resistant microbes (2). Lee
et al. (4) estimated the cost difference to be $7,070–$20,489
per case between community-associated methicillin-resistant
Staphylococcus aureus and methicillin-susceptible S. aureus.
Solutions to tackle AMR include antimicrobial stewardship
measures, such as optimizing AB dosing.
Because of the associated antimicrobial toxicity, therapeutic
drug monitoring (TDM) is standard for the treatment with
glycopeptides and aminoglycosides. Studies have demonstrated
the valuable effects of TDM on clinical outcomes, resulting
in faster microbial eradication and lesser nephrotoxicity (5,
6). ABs with a wider therapeutic index than those of
relatively toxic agents have not been thoroughly studied,
despite their harmful propensity to accumulate in the case
of kidney injury (7). Therefore, TDM is recommended in
patients treated with cefepime who have kidney injury and a
bacterial minimal inhibitory concentration (MIC) >8 mg/L (8).
Critical illness, multi-morbidity, age, and polypharmacy further
affect AB pharmacokinetics and pharmacodynamics (7, 9–12).
Therefore, appropriate dosing becomes crucial but remains an
unsolved issue (11). Recent efforts to develop a fast TDM
technique using mass spectrometry for serum sample analysis
have shown promising results (13, 14) but remains invasive,
expensive and lab-independent. However, although TDM may
improve the therapeutic target attainment, an easy-to-use,
reliable, non-invasive, and laboratory-independent TDM is still
lacking (15, 16).
Sweat is one of the most under-analyzed biological fluids,
despite its content of different proteins, hormones, and
metabolites (17, 18). Høiby et al. detected ciprofloxacin and
β-lactam ABs in the sweat of healthy study participants (19,
20). The molecular solubility (hydrophilic or lipophilic) as well
as the molecular size have to be seen as two of the main
physiological drivers of pharmacological secretion into sweat
(21). Those drivers are of importance in relation to the different
sweat collection methods such as the induced or passive sweat
collection and the specific body collection area. Newly developed
sensors, such as the on-skin spot-enzyme-linked immunosorbent
assay (ELISA), detect digital biomarkers in sweat (22). These
sensors facilitate laboratory-independent sweat analysis and may
potentially shape the future of healthcare diagnostics.
Here we investigated the detectability of the β-lactam ABs
cefepime, imipenem, and flucloxacillin in patients’ sweat and
to the best of our knowledge, sweat analysis was assessed as
a potential non-invasive AB drug monitoring strategy for the
first time.
MATERIALS AND METHODS
Study Design and Ethics
We conducted an observational pilot study with inpatients
recruited from the University Hospital Basel, Switzerland. The
trial lasted from September 2018 to June 2019. The patient sample
size was chosen to generate the first pilot data with a reasonable
amount of resources and time frame. The Ethics Committee
of Northwest and Central Switzerland (EKNZ Reg-ID 2018-
01155) approved this study, and all patients provided written
informed consent. The ClinicalTrials.gov registration number
is NCT03678142.
Inclusion and Exclusion Criteria
The study included patients who had been treated with
intravenous β-lactam ABs (cefepime, imipenem, and
flucloxacillin) for >24 h, had an estimated glomerular filtration
rate (eGFR) >50 mL·min−1·1.73 m(2)−1 and were >18 years
old. Patients were excluded if they were allergic to pilocarpine or
were receiving continuous oxygen supplementation.
Bio-Fluid Sampling
Sweat samples were collected 4 h after starting the last imipenem
and flucloxacillin infusions. For cefepime, the sweat and blood
samples were collected at baseline (BL, before) and 2, 4, 6, and
8 h after administration. Sweat was induced and collected using a
standardized method. Briefly, local eccrine sweat glands of the
volar lower arm were stimulated for 5min using pilocarpine
iontophoresis. Sweat samples were collected using a CE certified
MacroductTM sweat collector for ∼30min and transferred to
storage containers on dry ice (23). Sweat samples were stabilized
by adding 1 µL HaltTM protease inhibitor cocktail (100×) and
stored at−80◦C.
During sweat gland stimulation in patients administered
cefepime, we simultaneously collected reference blood samples,
which were transported on dry ice and stored at −80◦C.
Standard laboratory parameters were included in the analysis
(creatinine, eGFR, ALT, AST, gamma-glutamyltransferase,
alkaline phosphatase, and bilirubin), and demographic data,
such as age, weight, medication, and vital signs, were collected.
Bio-fluid samples were transported on dry ice to Colorado
State University, CO, USA. Bio-fluid analysis was conducted
by the Proteomic and Metabolomic Facility of Colorado State
University, CO, USA.
Quantification of ABs Using
Ultra-High-Performance Liquid
Chromatography Coupled With Triple
Quadrupole Mass Spectrometry
(UPLC-QqQ-MS)
The mass spectrometer was operated in the multiple reaction
monitoring (MRM) mode. In this mode, a parent ion is selected
by the first quadrupole, fragmented in the collision cell, and then
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a fragment ion(s) is selected by the third quadrupole. Product
ions, collision energies, and cone voltages were optimized for
each analyte by direct injection of individual synthetic standards
and their stable isotope-labeled internal standards (IS). Samples
were injected into a reverse phase UPLC column, and target
analytes and IS samples were eluted at specific retention times.
A calibration curve was generated using authentic standards
of each compound, and their corresponding stable isotope-
labeled IS in 50% methanol:50% artificial sweat (https://www.
pickeringtestsolutions.com/AP-eccrine/). The peak area values of
target analytes were normalized to those of the appropriate IS and
were plotted against expected concentrations ranging from 0.28
to 1,500 ng/mL.
AB Extraction From Human Whole Blood
for LC-MS Analysis
To extract the ABs, blood samples were thawed on ice, and 100
µL of each was placed into a 2.0mL polypropylene microfuge
tube. Then, 900 µL ice-cold methanol (spiked with 275 ng/mL
of cefepime-d3) was added to each sample and vortexed for
10min at 4◦C. Samples were stored at −80◦C for a minimum
of 1 h to facilitate protein precipitation. Precipitated proteins
were collected by centrifugation at 15,000 × g for 20min at
4◦C, then 900 µL of the supernatant was collected into 2mL
autosampler vials.
AB Extraction From Human Eccrine Sweat
for LC-MS Analysis
Sweat samples (50 µL) were diluted 1:1 (v/v) with 100%
methanol (spiked with 500 ng/mL meropenem-d6, cefepime d3,
and flucloxacillin-13C4). Each sample was briefly vortexed, then
50 µL was transferred into autosampler vials.
Standard Curve and Is Mixture
Authentic standards of imipenem, flucloxacillin, and cefepime
were diluted from 1 mg/mL library stocks to a 10µg/mL master
mix. Isotopically-labeled IS samples were diluted from 1 mg/mL
library stocks to a 2.5µg/mL IS-Master Mix, which was further
diluted with artificial sweat (Pickering Laboratories, Mountain
View, CA, USA) at a concentration of 500 ng/mL (IS-Artificial
Sweat). To construct the standard curve, the standard master mix
in 100% methanol was serially diluted 3.2 times from 25 ng/mL
to 0.28 ng/mL in 100% methanol. Then, 0.1mL of each methanol
dilution was added to 0.1mL of IS-Artificial Sweat, and the final
concentration of the IS was 250 ng/mL.
UPLC-QqQ-MS Analysis
LC-MS/MS was performed using a Waters Acquity UPLC
coupled with a Waters Xevo TQ-S QqQ mass spectrometer.
Chromatographic separations were conducted using a Waters
UPLC T3 C18 stationary phase (1 × 50mm, 1.7µM) column.
Mobile phases were 99.9% acetonitrile with 0.1% formic acid
(B) and 99.9% water with 0.1% formic acid (A). The analytical
gradient schedule was as follows: 0min, 0.1% B; 1.0min, 0.1%
B; 2.5min, 99% B; 3.5min, 99% B; 3.55min, 0.1% B; and 5min,
0.1% B. The flow rate was 800 µL/min and injection volume
was 5 µL. Samples were held at 6◦C in the autosampler, and the
column was operated at 45◦C. The MS was operated in positive
ionization mode with the capillary voltage set to 3 kV. The inter-
channel delay was set to 3ms, and the source and desolvation
temperatures were 150 and 500◦C, respectively. Desolvation and
cone gas flow rates were 1,000 and 150 L/h, while the collision
gas flow was 0.2 mL/min. The nebulizer pressure (nitrogen) was
set to 7 bar, and argon was the collision gas. The MS acquisition
functions were scheduled by retention time and provided 30 s
windows. Autodwell feature was set for each function, and the
dwell time was automatically calculated, while 12 points across
a peak were specified as the minimum data points per peak,
resulting in a minimum dwell time of 0.017 s.
Data and Statistical Analysis
All raw data files were imported into the Skyline open-source
software package (24). Each target analyte was visually inspected
for retention time and peak area integration. Peak areas were
extracted for target compounds detected in biological samples
and normalized to the peak area of the appropriate IS or
surrogate in each sample. Normalized peak areas were exported
to Excel, and absolute quantitation was obtained using the
linear regression equation generated for each compound from
the calibration curve. Limits of detection (LOD) and limits
of quantification (LOQ) were calculated as 3 or 10 times the
standard deviation (SD) of the blank divided by the slope of the
calibration curve, respectively (25, 26).
Quality Control (QC)
Study-specific quality control (QC) samples were generated to
represent the pool of all samples. They were injected into the
system after every seven samples were analyzed.
RESULTS
Patients
We recruited 13 patients, from which four were treated
with flucloxacillin and cefepime, and three were administered
imipenem. One patient was treated with a combination of
imipenem and cefepime and was included for both groups, but a
protocol violation occurred for imipenem (AB treatment<24 h).
However, the samples were still included because the study was
observational (Figure 1). One cefepime sweat sample was lost
because of sample mishandling; one pair of cefepime sweat and
blood samples could not be collected because the patient did not
attend the follow-up visit.
Patient characteristics are shown in Table 1 with a detailed
summary available as Tables S1–S3. Patients were aged 34 to 90
years with kidney function (eGFR) values ranging from 58 to
124 mL·min−1·1.73 m(2)−1, and their indications for AB therapy
varied from osteomyelitis to pneumonia.
Detection of ABs in Sweat
In this study, cefepime, flucloxacillin, and imipenem were
detected for the first time in all of the respective human eccrine
sweat (Tables 2–4). Sweat sample volumes ranged from 25 to
50 µl.
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FIGURE 1 | Patient flowchart: inclusion and exclusion of study patients.
TABLE 1 | Study population characteristics.
Characteristics Flucloxacillin
(n = 4)
Imipenem
(n = 4)
Cefepime
(n = 5)
Total
(n = 13)
Age (y),
mean ± SD
63.5 ± 21.0 63.2 ± 19.5 65.6 ± 22.4 64.2 ± 19.4
Male sex, n (%) 2 (50) 2 (50) 3 (60) 7 (53.8)
GFR (ml/min/1.73
m2 ), mean ± SD
92.0 ± 15.25 96.5 ± 23.1 92.8 ± 25.4 93.7 ± 20.25
Body temperature
(◦C), mean ± SD
36.8 ± 0.5 36.9 ± 0.7 37.1 ± 0.4 36.8 ± 0.5
Chronic kidney
disease, n (%)
0 (0) 1 (25) 1 (20) 2 (15.4)
Diabetes mellitus,
n (%)
0 (0) 2 (50) 1 (20) 3 (23.1)
Number of
comorbidities
4 11 7 22
CRP (mg/l),
mean ± SD
114.9 ± 99.0 135.65 ± 123.93 74.9 ± 88.4 105.9 ± 98.06
y, years; n, number; GFR, glomerular filtration rate; CRP, c-reactive-protein; SD,
standard deviation.
1. Patients treated with cefepime had a mean AB concentration
of 0.31 and 32.72 mg/L in sweat and blood, respectively.
Cefepime was detected in all sweat samples of patients
receiving AB (Table 2).
TABLE 2 | Antibiotic concentrations in the sweat and blood of patients treated
with cefepime.
Cefepime
concentration (mg/L)
Patient
1 (C1)
Patient
2 (C2)
Patient
3 (C3)
Patient
4 (C4)
Patient
5 (C5)
SWEAT
Time
BL 1.253 0.080 0.011 0.036 0.368
BL+2 h 3.422 0.041 0.045 NA 0.768
BL+4 h 0.215 0.029 0.033 0.096 0.094
BL+6 h 0.074 0.007 0.016 NA 0.133
BL+8 h 0.785 0.023 0.022 0.060 0.099
Mean 1.150 0.036 0.025 0.065 0.292
BLOOD
Time
BL 20.285 3.947 7.613 5.824 159.948
BL+2 h 67.016 33.630 18.599 34.667 59.736
BL+4 h 42.930 20.713 23.421 10.142 59.929
BL+6 h 38.587 12.321 14.967 NA 63.684
BL+8 h 37.233 13.157 13.728 3.958 38.415
Mean 41.210 16.754 15.666 13.648 76.342
BL, baseline before antibiotic treatment application; NA, not available.
2. Patients treated with flucloxacillin showed a mean AB
concentration of 0.83 mg/L 4 h in sweat after the start of the
infusion. Flucloxacillin was detected in all sweat samples of
patients receiving AB (Table 3).
Frontiers in Medicine | www.frontiersin.org 4 August 2020 | Volume 7 | Article 476
Brasier et al. Non-invasive β-Lactam Drug Monitoring
3. Patients treated with imipenem exhibited a mean AB
concentration of 0.04 mg/L 4 h in sweat after the start of
the infusion. Imipenem was detected in all sweat samples of
patients receiving AB (Table 4).
TABLE 3 | Antibiotic concentrations in the sweat of patients treated with
flucloxacillin.
Flucloxacillin
concentration (mg/L)
in sweat
Patient
1 (F1)
Patient
2 (F2)
Patient
3 (F3)
Patient
4 (F4)
Mean
TIME
BL+4 h 0.059 0.082 0.877 2.290 0.827
BL, baseline before antibiotic treatment initiation.
TABLE 4 | Antibiotic concentrations in the sweat of patients treated with
imipenem.
Imipenem
Concentration (mg/L)
in sweat
Patient
1 (I1)
Patient
2 (I2)
Patient
3 (I3)
Patient
4 (I4)
Mean
TIME
BL NA NA NA 0.004 0.004
BL+4 h 0.014 0.037 0.050 0.052 0.038
BL+8 h NA NA NA 0.046 0.046
BL, baseline before antibiotic treatment initiation; NA, not available.
The highest interpersonal AB sweat concentration variation was
detected between patients treated with cefepime at 2 h with values
of 0.041 mg/L (Patient C2) compared to 3.422 mg/L (Patient C1),
corresponding to a variation factor of 84 (Table 2). The lowest
interpersonal AB concentration variation was found between
patients treated with imipenem with a variation factor of 3.6
(Table 4).
Pharmacokinetic Monitoring of Cefepime
in Sweat
Cefepime AB concentration changes over time showed similar
dynamics in blood and sweat (Figures 2A–F). The mean AB
concentration of cefepime in sweat and blood ranged from
0.036 to 1.15 mg/L and 13.648 to 76·342 mg/L, respectively
(Table 2). Sweat concentrations showed the highest variation 2 h
after BL with a factor of 84 (Patients C1 and C2, Table 2) with
comparable dynamics in concentration changes (Figure 2A).
Patient C2 showed similar trends in samples analyzed at 2, 4,
6, and 8 h after BL (Figure 2B). In patient C3, after an earlier
increase in sweat cefepime concentrations compared to blood
concentrations, samples analyzed 4, 6, and 8 h after BL showed
simultaneous changes in both sweat and blood. Importantly,
patient C3 was administered the lowest cumulative daily AB dose
(single dose of 1,000mg at BL), which resulted in the lowest mean
AB concentration in sweat and a prolonged concentration peak
in the blood (Figure 2C). Patient C5 showed the highest total
mean concentration of cefepime in the blood (76.342 mg/L), but
FIGURE 2 | Detection of cefepime: sweat and blood concentrations of patients treated with cefepime over time. Sweat and blood concentrations of (A) patient 1, (B)
patient 2, (C) patient 3, (D) patient 4, and (E) patient 5; (F) Overview of the sweat and blood concentrations of patients 1–5.
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concentration changes in blood and sweat of patient C5 showed
a delay of 2 h compared to those of patients C1, C2, and C3
(Figure 2E).
In all patients treated with cefepime, the interpersonal factor
of variability derived from the maximum peak concentration
variability was higher in sweat (3.422 [maximum]/0.041 mg/L
[minimum]) = 84 [factor]) than in blood (159.948/3.947 mg/L
= 41). Analysis of the highest variation of trough levels detected
in patients showed a slightly higher interpersonal concentration
variability with sweat (0.074/0.007 mg/L = 11) than with blood
(38.415/3.947 mg/L = 10). By dividing the patients into two
groups based on age (>60 years) and kidney function (eGFR <
85 mL·min−1·1.75 m(2)−1), the concentration variability factor
reduced substantially for maximum and trough levels. The
maximum concentration variability factor of sweat decreased
from an initial value of 84 to 2 (0.096/0.045 mg/L) in the
younger patients and 5 (3.422/0.768 mg/L) in older patients.
In blood samples, the maximum concentration variability factor
decreased from 40 to 1 (34.667/33.630 mg/L) in young patients
and 2 (159.948/67.016 mg/L) in older patients. A comparison
of patient trough levels between the two age groups showed a
sweat concentration variability factor of 2 (0.011/0.007 mg/L) in
young patients and 1 (0.094/0.074 mg/L) in older patients. Serum
trough levels showed a cefepime concentration variability factor
of 1 (3.958/3.947 mg/L) in younger patients and 2 (38.415/20.285
mg/L) in older patients. Further, the gap between mean blood
and sweat AB concentrations was substantially smaller in the
older patients (patient C1: 41.210/1.150 mg/L = 36, patient C5:
76.342/0.292 mg/L = 261) than in younger patients (patient
C2: 16.754/0.036 mg/L = 465, patient C3: 15.666/0.025 mg/L =
Factor 627).
The elimination rate constant (Ke) showed comparable values
in sweat and blood in younger patients with adequate GFR
(patient 2: Ke was 0.16/h in sweat and 0.17/h in blood, patient 3:
Ke was 0.14/h in sweat and 0.13/h in blood, patient 4: Ke was not
calculated due to missing values). In older patients, Ke diverged
widely compared to younger patients, and showed the widest
divergence in the oldest patient (patient 1: Ke was 0.27/h in sweat
and 0.09/h in blood, patient 5: Ke is 0.22/h in sweat and 0.14/h
in blood).
DISCUSSION
This pilot study evaluated the potential of a novel non-invasive
AB drug monitoring strategy by sweat analysis in patients treated
with intravenous β-lactam ABs. We demonstrated that cefepime,
flucloxacillin, and imipenem were detectable in 100% of patient
sweat samples.
Flucloxacillin showed the highest mean AB concentration
in sweat. This was expectable because the main indications
for flucloxacillin are bacterial soft tissue infections due to its
established soft tissue penetration (27). Our novel approach
to AB treatment monitoring of soft tissue infections could
enable personalized treatment dosing. It could also ensure
adequate local AB concentrations above the minimal inhibitory
concentration (MIC) of the pathogen, which may improve
patient outcomes. The European Committee on Antimicrobial
Susceptibility Testing (EUCAST) has increasingly investigated
and proposed clinical MIC breakpoints of bacterial strains,
which may be used as target concentrations for TDM by sweat
analysis (28).
Interpersonal concentration variability of cefepime in blood
and sweat is considered very low when considering age and GFR.
It is important to point out that all cefepime concentrations
in blood samples of the older patient group were >20 mg/L,
including trough plasma levels, which is associated with severe
toxicities (29). This further indicates the need for personalized
AB TDM not only to prevent the development of resistance but
also to protect patients from toxic side effects. The varying mean
cefepime concentrations in the sweat and blood of patients of
different ages may be partially explained by lower main body
water volume and different sweat patterns between different
age groups, suggesting that patient age and GFR should be
taken into consideration for dose optimization (30). The wider
divergence of KE in sweat and blood along older patients with
lower GFR needs to be further considered, as AB concentrations
in sweat may underestimate blood concentrations in older
patients. This will need further evaluation and testing. The
only patient co-treated with cefepime and imipenem showed
imipenem concentrations in sweat after the first treatment and,
therefore, potentially qualifies as an AB monitoring that can
begin at treatment initiation.
Smartphone-based sweat sensor technologies are under
development and will soon be available for clinical testing and
implementation (31). Once they are available, this non-invasive
AB monitoring tool would be a highly promising resource
for on-demand personalized AB treatment. In combination
with smartphones, these biosensors would enable laboratory-
independent drug monitoring in sweat, which can be used
without the need for direct health care access (31).
Despite the promising results, this study has a few limitations.
Pilocarpine iontophoresis was conducted under standardized
conditions for 5min, followed by sweat sampling for 30
min. Differences occur in sweat volume and composition of
electrolytes if excessive sweating is prolonged. Therefore, a
more advanced method that would enable spot measurements is
needed to verify these results. Combining the analysis of sweat
with that of vital signs such as body temperature and sweat rate
would allow a more standardized sampling approach.
Despite instant sample cooling, the on-skin sweat sampling
procedure and the analysis processing times should be considered
during the interpretation of results. Cefepime is known to
be unstable at body temperature (32); therefore, absolute
sweat concentrations should be carefully interpreted and
confirmed using spot measurements. Nevertheless, the detection
of concentration changes of cefepime in sweat and blood samples
remains highly promising.
The Macroduct sweat collector is an established medical
device that actively stimulates sweat glands using pilocarpine
iontophoresis with a standardized protocol (23). Although this is
the most standardized sampling modality, especially in patients,
it is not clear whether activating sweat glands is the most reliable
procedure. It is of importance in regard to different medication
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characteristics such as the lipid solubility. As actively induced
eccrine sweat glands secret basically water- and salt-based liquids,
an actively induced sweat gland stimulation may not be the best
approach for lipophilic compounds (33). Further investigations
of active and passive sweat sampling is needed.
Due to internal sample processes, blood samples were directly
frozen after sampling, and vortexed along thawing processes
during sample analysis. β-lactam antibiotics are very unlikely
to accumulate intracellularly (34). Therefore, we assume that
human intracellular concentrations are negligible for this first
pilot project.
Finally, the sample size was very small, and more patients
need to be investigated. Nevertheless, this novel approach has
high potential to serve as the first non-invasive AB monitoring
tool. Trials correlating AB sweat concentrations with clinical
outcome to verify the efficacy of sweat analysis in AB TDM
are needed.
This study revealed the high potential of sweat analysis to
revolutionize antimicrobial TDM. AB concentration changes
in sweat and blood showed comparable dynamics and were
quickly detectable. Considering the heterogeneity of the
patient population, sweat analysis—in combination with next-
generation smartphone-based biosensors—is a novel and highly
promising approach. Further, the detection of ABs in sweat
could serve as an indicator of local tissue concentrations that
could significantly impact the prevention and treatment of soft
tissue infections.
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